Oxford BioMedica PLC
LSE:OXB

Watchlist Manager
Oxford BioMedica PLC Logo
Oxford BioMedica PLC
LSE:OXB
Watchlist
Price: 420 GBX 1.82% Market Closed
Market Cap: 444.9m GBX
Have any thoughts about
Oxford BioMedica PLC?
Write Note

Relative Value

The Relative Value of one OXB stock under the Base Case scenario is 692.82 GBX. Compared to the current market price of 420 GBX, Oxford BioMedica PLC is Undervalued by 39%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

OXB Relative Value
Base Case
692.82 GBX
Undervaluation 39%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
46
vs Industry
69
Median 3Y
3.2
Median 5Y
4.4
Industry
7.7
Forward
3.3
vs History
vs Industry
10
Median 3Y
-2.8
Median 5Y
-10.7
Industry
22.7
Forward
-10.1
vs History
vs Industry
4
Median 3Y
-6.3
Median 5Y
-6.9
Industry
21.6
vs History
vs Industry
8
Median 3Y
-3.7
Median 5Y
-5.4
Industry
25.2
vs History
22
vs Industry
19
Median 3Y
2.5
Median 5Y
5.3
Industry
2.5
vs History
44
vs Industry
59
Median 3Y
3.1
Median 5Y
4.4
Industry
7.7
Forward
3.5
vs History
38
vs Industry
42
Median 3Y
5.6
Median 5Y
10.4
Industry
9
vs History
vs Industry
15
Median 3Y
-7.2
Median 5Y
-9.1
Industry
4.2
Forward
-40.5
vs History
vs Industry
13
Median 3Y
-4.6
Median 5Y
-7.5
Industry
4.1
Forward
-11.2
vs History
vs Industry
4
Median 3Y
-6.7
Median 5Y
-7.2
Industry
5.7
vs History
vs Industry
11
Median 3Y
-7.4
Median 5Y
-13.4
Industry
3.6
vs History
50
vs Industry
44
Median 3Y
1.5
Median 5Y
3.2
Industry
4.6

Multiples Across Competitors

OXB Competitors Multiples
Oxford BioMedica PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Oxford BioMedica PLC
LSE:OXB
439.6m GBP 4.5 -3.1 -11.1 -6.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 5.9 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.5 -129.9 -104.5 -76.2
P/E Multiple
Earnings Growth
UK
Oxford BioMedica PLC
LSE:OXB
Average P/E: 208.3
Negative Multiple: -3.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
UK
Oxford BioMedica PLC
LSE:OXB
Average EV/EBITDA: 17.2
Negative Multiple: -11.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
UK
Oxford BioMedica PLC
LSE:OXB
Average EV/EBIT: 22.5
Negative Multiple: -6.9
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

See Also

Discover More
Back to Top